NEW YORK, NY--(Marketwired - Oct 10, 2013) - IntelliCell Biosciences, Inc. (
The influx of capital structure will allow, the Company to expand its FDA cGTP cellular laboratories into Hospitals and Ambulatory Surgical Centers. This will also enable IntelliCell to initiate a FDA IND clinical study, vital for the development of the company.
Dr. Steven Victor said, "I am privileged that Mr. Owen May, Managing Director of MD Global Partners, is going to lead in the Company's restructuring and strategic positioning. With his years of experience and expertise, Mr. May will be instrumental in assisting us to achieve our strategic milestones. Mr. May, a graduate of Duke University's Fuqua School of Business, is a seasoned professional with decades of experience in helping assisting emerging growth companies, similar to IntelliCell achieve their goals."
Dr. Steven Victor, Chairman and CEO of IntelliCell Biosciences, commented, "IntelliCell believes that we possess a paradigm shifting discovery that will change the manner in which patients are treated," Dr. Victor continued. "We are confident that our relationships with the FDA and other governing bodies will allow us to rapidly expand the number of patients that physicians at ReGen Medical, PC can treat using IntelliCell's SFV cellular therapy."
About MD Global Partners
MD Global Partners, LLC ("MDG") is an independent full service investment bank focused on small to middle market public and private companies. The Firm brings an integrated strategic, operating and financial approach in assisting small companies realize the benefits of conventional investment banking services throughout the life cycle. Its senior team has extensive transaction execution experience and strong relationships with a variety of investors including family offices and individual/institutional investors, both domestic and global. MDG's wide spectrum of service offerings combined with its global, diverse investor network, uniquely positions itself to provide advice and find optimal investor groups to its clients.
About IntelliCell Biosciences
IntelliCell is a pioneering regenerative medicine company focused on the expanding regenerative medical markets using adult autologous stromal vascular fraction cells (SVFCs) derived from the blood vessels in the adult adipose tissue. IntelliCell Biosciences has developed its own patented technology and protocol to separate adult autologous vascular cells from adipose tissue without the use of enzymes. One of the revenue streams IntelliCell is pursuing is placing its labs into Hospitals and Ambulatory Surgical Centers. IntelliCell will also be seeking to develop technology-licensing agreements with technology developers, universities, and international business entities.
Certain statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "will reach," "will change," "will soon," "should," "could," "would," "may," "can" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.